• Explore /
  • Poster
  • / A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and <em>EGFR</em> mutation–positive non-small cell lung cancer (OPEN/TORG2040).

A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).

Abstract Poster

Authors

null

Nobuaki Mamesaya

Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan

Nobuaki Mamesaya , Tomoya Fukui , Toshiaki Takahashi , Kazuma Kishi , Takahiro Yoshizawa , Takaaki Tokito , Koichi Azuma , Kei Morikawa , Yusuke Okuma , Hiroshige Yoshioka , Shinobu Hosokawa , Takashi Kasai , Ken Masubuchi , Shinji Nakamichi , Masaharu Aga , Jiichiro Sasaki , Satoshi Igawa , Akiko Kada , Katsuhiko Naoki , Hiroaki Okamoto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

jRCTs041200100

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 8552)

DOI

10.1200/JCO.2024.42.16_suppl.8552

Abstract #

8552

Poster Bd #

416

Abstract Disclosures

Similar Posters

First Author: Gongyan Chen

First Author: Mariano Provencio-Pulla

First Author: Helena Alexandra Yu

First Author: Kiyoaki Uryu